Exhibit 99.1

Cardinal Health, Inc. and Subsidiaries

Segment Information

	Fiscal Year 2022										Fiscal Year 2023															Fiscal Year 2024
(in millions)	Q1		Q2		Q3		Q4		Full Year		Q1			Q2			Q3			Q4			Full Year			Q1			Q2			YTD
Segment Revenue
Pharmaceutical and Specialty Solutions	$	39,614	$	41,166	$	40,727	$	43,080	$	164,587	$	45,550		$	47,395		$	46,496		$	49,379		$	188,820		$	50,683		$	53,190		$	103,873
Growth Rate											15		%	15		%	14		%	15		%	15		%	11		%	12		%	12		%
Global Medical Products and Distribution	3,532		3,404		3,241		3,119		13,296		3,096			3,055			2,989			3,054			12,194			3,032			3,119			6,151
Growth Rate											(12)		%	(10)		%	(8)		%	(2)		%	(8)		%	(2)		%	2		%	—		%
Other	838		904		887		920		3,549		976			1,037			1,025			1,039			4,077			1,069			1,156			2,225
Growth Rate											16		%	15		%	16		%	13		%	15		%	10		%	11		%	11		%
Total Segment Revenue 1,2	$	43,984	$	45,474	$	44,855	$	47,119	$	181,432	$	49,622		$	51,487		$	50,510		$	53,472		$	205,091		$	54,784		$	57,465		$	112,249
Growth Rate											13		%	13		%	13		%	13		%	13		%	10		%	12		%	11		%
	Q1		Q2		Q3		Q4		Full Year		Q1			Q2			Q3			Q4			Full Year			Q1			Q2			YTD
Segment Profit
Pharmaceutical and Specialty Solutions	$	375	$	401	$	454	$	411	$	1,641	$	399		$	435		$	560		$	468		$	1,862		$	472		$	489		$	961
Growth Rate											6		%	8		%	23		%	14		%	13		%	18		%	12		%	15		%
Global Medical Products and Distribution	58		(24)		(2)		(81)		(49)		(75)			(54)			(46)			13			(162)			1			(3)			(2)
Growth Rate											N.M.			N.M.			N.M.			N.M.			N.M.			N.M.			N.M.			N.M.
Other	96		99		94		105		394		99			100			106			105			410			105			103			208
Growth Rate											3		%	1		%	13		%	—		%	4		%	6		%	3		%	5		%
Total Segment Profit 1,2	$	529	$	476	$	546	$	435	$	1,986	$	423		$	481		$	620		$	586		$	2,110		$	578		$	589		$	1,167
Growth Rate											(20)		%	1		%	14		%	35		%	6		%	37		%	22		%	29		%

1 These totals do not include certain items recorded in Corporate which are not allocated to the segments. There are no changes to the company's previously reported total consolidated revenue or operating earnings/(loss).

2 The recast segment results reflect changes in the elimination of inter-segment revenue and allocated corporate expenses for shared functions, which are driven by the reporting structure change effective in the third quarter of fiscal 2024. For example, reflecting the changes in allocated corporate expenses, segment profit for the former Pharmaceutical Segment would have decreased by $10M and $13M in fiscal 2023 and fiscal 2022, respectively, with corresponding increases to segment profit for the former Medical Segment.

The sum of the components and certain computations may reflect rounding adjustments.